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Abstract
During the recent period, dermoscopy has yielded improvement in
the early disclosure of various atypical melanocytic neoplasms (AMN)
of the skin. Beyond this clinical procedure, AMN histopathology
remains mandatory for establishing their precise diagnosis. Of note,
panels of experts in AMN merely report moderate agreement in vari-
ous puzzling cases. Divergences in opinion and misdiagnosis are like-
ly increased when histopathological criteria are not fine-tuned and
when facing a diversity of AMN types. Furthermore, some AMN have
been differently named in the literature including atypical Spitz tumor,
metastasizing Spitz tumor, borderline and intermediate melanocytic
tumor, malignant Spitz nevus, pigmented epithelioid melanocytoma or
animal-type melanoma. Some acronyms have been further suggested
such as MELTUMP (after melanocytic tumor of uncertain malignant
potential) and STUMP (after Spitzoid melanocytic tumor of uncertain
malignant potential). In this review, such AMN at the exclusion of
cutaneous malignant melanoma (MM) variants, are grouped under the
tentative broad heading skin melanocytoma. Such set of AMN fre-
quently follows an indolent course, although they exhibit atypical and
sometimes worrisome patterns or cytological atypia. Rare cases of skin
melanocytomas progress to loco regional clusters of lesions (agminate
melanocytomas), and even to regional lymph nodes. At times, the dis-
tinction between a skin melanocytoma and MM remains puzzling.
However, multipronged immunohistochemistry and emerging molecu-
lar biology help profiling any malignancy risk if present.
Introduction
In recent times, a progressive pace of changes took place in the inci-
dence of cutaneous malignant melanomas (MM) mostly affecting
Caucasian populations everywhere in the world.1 The observed rising MM
incidence was probably inflated by thorough clinical screenings using der-
moscopy disclosing more small size MM. The fear of this malignancy exerts
a major impact in the relationship between patients, dermatologists and
dermatopathologists. In connection with the medico-legal liability, the risk
of overcalling or conversely minimizing some disturbing lesions is a matter
of concern. The histopathological identification of MM is commonly undis-
puted for most expert dermatopathologists.2 However, the diagnosis is
occasionally less straightforward and remains controversial for some dis-
tinct atypical melanocytic neoplasms (AMN) of uncertain prognosis.3-5
Dysplastic nevi are important simulants of MM. Clinical and histopatholog-
ical criteria for diagnosis have been clearly delineated for dysplastic nevi.
A remarkable consensus prevails about the presence of dysplastic nevi as
risk markers for familial MM.6 The size of dysplastic nevi is larger than
common nevi. They show clinical asymmetry. Some color variegation and
a hint of border irregularity are commonly present. Criteria overlap to some
extent between enlarging dysplastic nevi and signs of the radial growth
phase of MM. The aspect of dysplastic nevi evolves over time, usually in the
direction of greater cell compactness. Contrasting with MM, there is no evi-
dence for partial regression in dysplastic nevi. The ugly duckling aspect of
dysplastic nevi evoked at the clinical inspection is commonly adequately
interpreted at dermoscopic and cyanoacrylate skin surface stripping exam-
inations.7 The regular histopathological examination represents the final
gold standard for ruling out MM in a concerned lesion. For a series of other
AMN, the current histopathological criteria for benignancy or malignancy
are not fully met or fail to make a sharp distinction between MM and AMN
with confidence.8 In fact, AMN encompass indolent, low-grade, but occa-
sionally seemingly looking as median-grade, and exceptionally high-grade
lesions. Experienced dermatopathologists commonly recognize the major
microscopic features, but some experts in the field occasionally question
the interpretations given to findings and the diagnostic proposals.4 In this
state of uncertainty, a few case reports have yielded borderline AMN, but
later showing metastases leading to death. This created a matter of confu-
sion and controversy. In many instances, such lesions were not scrutinized
using forefront immunohistochemistry. As described below, such laborato-
ry procedure usually highlights distinct aspects about the biology and
growth patterns linked to the potential evolution of AMN.
Quandaries about atypical melanocytic neo-
plasms diagnosis
A clear laboratory distinction is expected between MM and
melanocytic nevi, although it not always fulfilled. Some quandaries
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about MM and AMN diagnosis remain complex and puzzling. The prob-
lem was probably first raised in the literature about one century ago
when two French dermatologists, J. Darier and A. Civatte, described in
minute detail a worrying melanocytic tumor.9 The lesion was reported
to growth rapidly on the nose of a child, and both dermatologists were
thwarted in their efforts to rule on the benign or malignant nature of
the tumor. About four decades later, a new concept emerged following
observations made by S. Spitz who pointed to melanomas following a
benign course in young subjects.10 Since that time, the borderline
between Spitz tumors and MM remained uncertain in some
instances.11-15
Other melanocytic tumors exhibit atypical features somewhat mim-
icking MM. In some cases, a variety of triggering factors were identi-
fied.16-21 Presently, it remains that little progress has been performed in
identifying AMN etiologies because of the inability to accurately inter-
pret the histopathology and the biological potential of a set of lesions.
Future works on molecular biology will probably bring some insights in
this field.22
In the current literature, Spitz tumor and its variants showed a
marked expansion among the clinico-pathological AMN spectrum. As a
consequence, there is a risk of loosing specific diagnostic criteria for
the typical Spitz tumor, which should remain a distinct and recogniza-
ble entity. As another trend, the other groups of AMN have received var-
ious designations. They include pigmented epithelioid melanocytoma,
melanocytic dysplasia, deep penetrating nevus, minimal deviation MM,
borderline MM, intermediate melanocytic tumor, melanocytic tumor of
uncertain malignant potential (MELTUMP), spitzoid melanocytic
tumor of uncertain malignant potential (STUMP), malignant Spitz
nevus, metastasizing Spitz tumor, atypical Spitz tumor, spitzoid lesion
and still other denominations.8 The profusion of all these terms poten-
tially appears quite confusing. In the present work, the atypical but
indolent AMN variants are tentatively grouped under the global head-
ing skin melanocytoma.8
Skin melanocytoma in clinical perspective
Of note, the term melanocytoma was introduced in human pathology
(leptomeninges, eye)23,24 and animal skin pathology25-27 distinguishing
atypical but usually benign melanocytic neoplasms. There is mounting
evidence that skin melanocytomas represent neoplasms distinct from
common melanocytic nevi and MM. Such a distinction has found gen-
eral acceptance on a descriptive morphological level. It supports a clear-
er understanding for the benefit of the patients. It remains that the dis-
tinction between AMN and MM is occasionally difficult, and even
impossible. It remains that specific skin melanocytoma gene mutations
have not yet been identified. Some of them are possibly involved in
melanocytic nevus formation. 
Human histopathology presently represents the mainstay for routine
identification of AMN. Clinical features remain, however, of major
importance, and should not be disregarded. The term skin melanocy-
toma is used as an overall term encompassing AMN which do not meet
the regular histopathological criteria of any recognized type of
melanocytic nevus and MM.8,28 Such melanocytoma was initially select-
ed in human dermatopathology for distinguishing Spitz tumor and the
pigmented spindle cell tumor (Reed nevus) from regular melanocytic
nevi.28-30 Such a concept was further extended to a set of other AMN.8
Under diverse internal and external conditions, melanocytes and
nevocytes are possibly triggered, and some of them form skin
melanocytomas. A few specific endogenous (endocrine) messages,
genetic influences and environmental factors were identified in this
field. For instance, some skin melanocytomas develop on congenital
and dysplastic nevi,31 melanocytic nevi modified by pregnancy or oral
contraception,21,32 some nevi of subjects on growth hormone therapy,16
melanocytic nevi transitorily modified under ultraviolet-light irradia-
tion.33,34 The possibility of a skin melanocytoma should be evoked in
any of each single cases. Some of them represent an atypical progres-
sion step in the maturation of an otherwise benign melanocytic neo-
plasm. In humans, skin melanocytomas often occur singly.
Occasionally, a clusters of melanocytomas develop.18 Some of these
lesions are clustered (so-called agminate AMN) and arise incidentally
after removal of a solitary lesion.19
MM is more common in fair skinned Caucasian subjects.35,36 A sim-
ilar epidemiology for AMN supports the role of skin color as a risk factor
for such benign neoplasms. In Caucasian populations, sunburns and
sharp episodes of intense sun exposure during childhood were more
associated with relative MM risk compared to cumulative lifetime expo-
sure.37 The risk associated with sun exposure is no longer significant
once adjusted for the ability to tan and/or susceptibility to sunburn
defined in the Fitzpatrick skin types.38,39 Sunburns have been associat-
ed with MM, but the relative risks are low, around 1.5.36 Currently,
there is no report pointing to a causative relationship between intense
or chronic sun exposures and skin melanocytomas.
Different at risk phenotypes are associated with MM. The most pow-
erful predictors for MM are a high number of melanocytic nevi or, alter-
natively, recurrent photodamages with actinic keratoses. The number
of melanocytic nevi appears to be the strongest risk factor for MM with
an odds ratio in the order of 5 to 10, which is far greater than the rela-
tive risk for MM associated with sun exposure.40-43 The risk factors
associating MM with an excess of melanocytic nevi is consistent across
the world, even with variable levels of sun exposure.43 There are no sig-
nificant differences in the magnitude of relative risks for MM in rela-
tion to the number of nevi when comparing Australia and Europe find-
ings.40-43 By contrast, skin melanocytomas are not linked to any of
these risk predictors.
The evolution of MM discloses the relative contribution of genetics
and environmental impact in the set of risk factors. Mean age at diag-
nosis, body distribution of MM according to gender are similar among
different Caucasian populations. MM sites in both genders are differ-
ent with women more likely to have MM on the lower legs whilst men
are more likely to have MM on the trunk.44 Such gender difference is
similar across all latitudes showing that the extent in sun exposure
does not really affect body site MM locations, and that other genetically
determined gender-related factors affect MM. 
In our experience, the overall F/M sex ratio of skin melanocytomas
reaches 1.6 or so.8 The age distribution looks similar in both genders.
In general, most Spitz tumors occur before the early twentieth. By con-
trast, the prevalence of the other skin melanocytomas peaks during the
3rd and 4th decade of life. A sharp decrease is found after the age of 50
years. Such age and gender distributions somewhat resemble that of
MM.1
Skin melanocytoma: a simulator but not a pre-
cursor of malignant melanoma
For laypeople facing an AMN, there is commonly a lack of distinction
between the diagnosis and the expected outcome prediction. The diag-
nosis of MM is much more frightening than AMN diagnoses which are
perceived as reassuring. However, a gray area exists between the rec-
ognizable truly benign melanocytic neoplasms and MM. Diagnostic dis-
agreement is not exceptional among experts in both the clinical and
histopathological fields.4 The clinico-pathologic correlation remains of
importance in the diagnostic and prognostic evaluations of melanocytic
tumors.
Prognostic factors associated with AMN correspond to selective cri-










teria with expected reliability. As such, some biological factors recog-
nized to influence the neoplastic progression are frequently skipped
when providing a diagnostic opinion. Thus, there are possibly subsets
of non-metastasizing MM, as well as nevoid MM simulating benign
lesions and MM simulants. Clearly, some molecular and biological fea-
tures do not match exactly with the diagnosis stemmed from standard
microscopy of AMN. Some borderline AMN lesions give rise to metas-
tases in a minority of patients. Hence, misdiagnosis, but also some cur-
rently unpredictable natural outcomes, scientific uncertainties about
cancer progression, and practical limitations in the routine laboratory
practice concur to create a gap between the histopathological diagnosis
and the expectation of an accurate prognostic determination.
The discrimination between the diversity in these neoplasms is
hampered by interobserver variations in the interpretation of morpho-
logical aspects of AMN. Thus, the descriptive interpretations are occa-
sionally uncertain. The concept of skin melanocytoma is thus applied to
AMN looking like a Spitz tumor, but with variable atypical histopatho-
logical presentations. It remains that a group of AMN that does not
exhibit the current histopathological criteria of skin melanocytoma or
MM, do not allow an unequivocal diagnosis with confidence. From per-
sonal observations, immunohistochemistry helps distinguishing skin
melanocytomas from MM.8 Although data need further independent
confirmation, some of the parameters put forward prove to be robust
and applicable to routine diagnostic settings. Much remains to be
learned about the skin melanocytoma spectrum. Further studies should
gradually increase the diagnostic accuracy in the future. 
The most promising diagnostic immunopathological clues for distin-
guishing AMN from MM appear to be some immunostaining patterns
in nests of neoplastic cells with a given differentiation antibody. Of
note, uneven immunohistochemical patterns of neoplastic progression
markers are encountered in both skin melanocytomas and triggered
melanocytic nevi as well.
What next?
At this stage of conceptual consideration, MM are morphologically
distinct from the group of AMN. Various morphological presentations of
AMN are described with a common biological evolution. The AMN ten-
tatively gathered as skin melanocytomas cannot be defined by specific
morphological criteria, except that do not show those of MM. The most
typical exclusion criteria for benign AMN are a lack of cell maturation,
and presence of atypical and deep mitoses. By contrast, nuclear pleo-
morphism and high nuclear-cytoplasmic ratio, and numerous so-called
Kamino’s bodies are quite common in skin melanocytomas. A large ger-
minative compartment (high Ki-67 index) is occasionally present.
In the current literature, there is a lack of reports on a single major
genetic mutation defining any AMN. None of those that are identified
in MM are apparently expressed in AMN. It is, however, possible that
some genes regulating the cell cycle of proliferation should be involved
at some stages of AMN.
By and large, the AMN spectrum exhibits a variety of clinical and his-
tological presentations that are unified by a similar biological issue.
The AMN do not seem to be influenced by genders and a specific envi-
ronmental factor including sun exposures. General practitioners are
potentially at the frontline for early diagnosis. The global management
of the patient does not require a large and deep excision and a medical
follow-up.
The contribution of surrogate markers in the AMN diagnosis
remains to be scrutinized.8,27 A reduced expression of glutathione-S-
transferase has been documented in pigmented epithelioid melanocy-
tomas.45 This enzyme is a detoxifying agent,46 involved in tumor pro-
gression. A distinct potential means distinguishing various skin
melanocytomas and MM relies on their distinct expression of the  –1
and  –5 type IV collagen surrounding the tumoral nests.47 Still another
clue is possibly represented by the immunohistochemical expression of
disturbed HOX gene products.48
Molecular biology opens novel methods in the diagnostic field of skin
melanocytomas.49 At present, fluorescence in situ hybridization (FISH)
testing was used in lesions with borderline morphologies50,51 showing
molecular complexity and a variety of mutations. The chromosomal G
banding testing will probably provide superior information to FISH for
classifying skin melanocytomas and other AMN.52-54 In this field, vali-
dations against clinical presentations and evolutions are expected in
the future. Many of the early morphologic MM types correlate with
dominant mutations. In a near future, it is expected that some AMN
types will reveal mutations involved in stratifying risk, and will help to
identify some indolent skin melanocytomas.55
Conclusions
Skin melanocytomas represent a category of melanocytic neoplasms
on the borders between common melanocytic nevi and MM. They often
represent benign lesions with spontaneous limitations in both their
size and propensity for tissue invasion. However, their histopathologi-
cal presentations are commonly troublesome, and even worrying.
Selected immunohistochemistry helps for diagnostic and prognostic
purposes in melanocytic neoplasms. Information should be gathered
from a panel of antibodies in order to increase relevance of the findings
and to reduce part of the uncertainties. In particular, immunohisto-
chemistry evaluating the maturation and proliferation markers helps
distinguishing skin melanocytomas from MM. Multipronged immuno-
histochemistry and DNA molecular biology should be performed in
order to increase the diagnostic accuracy. 
Recent studies underscore the diversity of AMN. Such observations,
and any subsequent analogous research, will improve the ways to man-
age patients with AMN. By spreading the knowledge of skin melanocy-
toma variants, larger series of cases should be collected in the coming
years, making it possible to better determine the clinicopathological
characteristics of these tumors. It would be important to fine-tune spe-
cific (immuno-) histopathological aspects of skin melanocytomas. An
accurate follow-up of large series of cases will allow to better defining
the frontier between MM and indolent skin melanocytomas. Further
studies are still required to perceive and understand the etiology, the
risk factors and the best way to deal with skin melanocytomas.
Ultimately, bioactive compounds and topical pharmacologic agents
blocking any agent (growth factor, hormone) responsible for the skin
melanocytoma genesis and growth should be searched for.
It remains that in rare cases the distinction between skin melanocy-
tomas and MM proves to be difficult to establish. The prognosis is then
unpredictable and unclear. Future cytogenetic studies could possibly
uncover and help understanding the behavior of skin melanocytomas. 
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